Understanding Acute Dietary Changes After GLP-1 Agonist Treatment: The GLaD Feasibility Study

Launched by AUSTRALIAN CATHOLIC UNIVERSITY · Jun 1, 2025

Keywords

ClinConnect Summary

The GLaD Feasibility Study is a research project designed to learn more about how people change their eating habits after starting a specific type of medication called GLP-1 agonists, which are commonly used to help manage obesity and Type 2 diabetes. This study will involve individuals who are planning to begin this medication and are willing to keep track of what they eat, as well as answer questions about their behavior and mental well-being.

To participate in this study, you need to be at least 18 years old and planning to start a GLP-1 agonist medication, such as Ozempic or Saxenda, for the first time. It's important that you haven't used any GLP-1 medications in the past six months. Participants will not only help researchers gather valuable information but will also get a chance to reflect on their dietary choices and health. This study is currently not recruiting participants, but if you meet the criteria, you may be contacted when it starts.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Aged 18+ years old
• • Intending to commence a prescription for a GLP-1 agonist (may be dual agonist, i.e. Ozempic, Trulicity, Monjaro, or Saxenda) medication, with no use in the previous 6 months
• • The primary reason for commencing the medication will be for diabetes or weight management
• • Willing to participate in dietary recall and questionnaires
• Exclusion Criteria:
• • Aged under 18 years,
• • used a GLP-1 agonist medication in the previous 6 months,
• • unwilling or unable to provide dietary recalls
• • non-English speaking.